Although the current doctrine of IBD pathogenesis proposes an interaction between environmental factors and gut microbiota in genetically susceptible individuals, dietary exposures have attracted recent interest and are, at least in part, likely to explain the rapid rise in disease incidence and prevalence. The D-ECCO working group along with other ECCO experts with expertise in nutrition, microbiology, physiology, and medicine reviewed the evidence investigating the role of diet and nutritional therapy in the onset, perpetuation, and management of IBD. A narrative topical review is presented where evidence pertinent to the topic is summarised collectively under three main thematic domains: i] the role of diet as an environmental factor in IBD aetiology; ii] the role of diet as induction and maintenance therapy in IBD; and iii] assessment of nutritional status and supportive nutritional therapy in IBD. A summary of research gaps for each of these thematic domains is proposed, which is anticipated to be agenda-setting for future research in the area of diet and nutrition in IBD.
Introduction
The current dogma of inflammatory bowel disease [IBD] pathogenesis involves a complex, yet elusive, interaction between environmental factors and the gut microbiota in people who are genetically predisposed. However, the rapid rise in global prevalence of both ulcerative colitis [UC] and Crohn's disease [CD] cannot be attributed to human genetics alone. 1 Evidence now proposes that whereas human genetics are important, they explain only a small fraction of the risk of developing the disease, with microbial determinants and other environmental exposures thought to be more important than genetic susceptibility. 2 Among environmental factors, dietary influences have attracted the most interest and are likely to significantly contribute to the rapid rise in disease epidemiology. 3 There are several lines of evidence to suggest that diet is a key player in the onset, perpetuation, and management of the disease: epidemiological evidence associates certain dietary nutrients and components with increased risk of IBD; exclusive enteral nutrition [EEN] is the primary induction treatment of active paediatric CD; and there is emerging evidence that exclusion diets could treat or prevent subsequent disease flare. As malnutrition is a frequent presenting symptom of IBD that fluctuates erratically during the course of the disease, assessment of malnutrition and supportive nutritional therapy are important aspects of the multidisciplinary management of patients with IBD. 4 In contrast to the efforts thus far to understand the genetic and microbial origins of IBD and the development of effective and sideeffect free pharmacological treatments in IBD, there is currently very little research on the role of nutrition or diet in these areas. As the current doctrine of IBD pathogenesis proposes a complex interplay between dietary influences, genetics, and environment in the aetiology of IBD, there is now a pressing need to review past and current research and identify gaps for future research. The aim of this topical review was to extensively review the literature on the role of diet and nutrition in the aetiology and management of IBD and set the agenda for future research.
Methodology
A contributors' group was assembled involving all members of the D-ECCO Working Group [https://www.ecco-ibd.eu/index.php/ about-ecco/ecco-operational-board/d-ecco-wg.htmland] and competitive application for membership of a Topical Review Group launched by ECCO. Selection of contributors was based on their curriculum vitae, a personal supporting statement, and ensuring equal representation of professions and countries, as dictated by ECCO instructions for topical reviews and advised by its Governing Board. Three main thematic areas were selected a priori and working groups and thematic leaders were assigned for each.
A thorough literature search was conducted using Medline and a combination of appropriate keywords and Boolean operators. Search was limited to articles published in English, and focus was given to recent evidence published over the past 15 years and until January 2016. Draft reports produced by each contributor were reviewed by the thematic leaders and project coordinators. The main research gaps were identified and agreed by consensus in a face-toface meeting involving all contributing authors in Amsterdam in March 2016. Consensus was defined as agreement of > 80% following blind electronic voting and discussion between contributors where required. The final manuscript for publication was reviewed by all members of the Topical Review Group and approved by the Governing Board of ECCO.
Role of diet as an environmental factor in IBD aetiology
2.1.1. Diet, microbiota and pathogenesis of IBD Diet can contribute to gastrointestinal health, either via direct effects on gut homeostasis and barrier function or indirectly via the intestinal microbiome [ Supplementary Figure 1 , available as Supplementary data at ECCO-JCC online]. This densely populated microbial community is shaped by host genetics and environmental factors, and comprises a limited number of phyla dominated by Bacteroidetes and Firmicutes. 5 It involves complex microbe-microbe and host-microbe interactions that vary along the gastrointestinal tract, with indispensable effects on host functions with regard to the immune system, epithelial and barrier function, and the large metabolic capacity. 6 Segregation into three robust clusters [i.e. 'enterotypes'] driven by Bacteroides, Prevotella, and Ruminococcus, 7 is associated with long-term dietary preferences, [high protein and fat consumption with the Bacteroides and carbohydrate-rich diets with the Prevotella enterotype]. 8 Others reported on a bimodal distribution in microbial gene richness, in which a lower richness was associated with impaired metabolic factors and inflammation 9 and being less responsive to dietary interventions. 10 The global increasing incidence in IBD seems to be associated with Western lifestyle. 11, 12 Diet can shape the microbiota composition and activity and impact on host-microbe interactions. Dietary intake of a high protein diet and/or red meat can result in increased production of bacterial metabolites, such as ammonia, indoles, phenols, and sulphide, that may be harmful to the gut. 13 On the other hand, bacterial fermentation of non-digestible carbohydrates results in short-chain fatty acids [SCFAs] which are an energy source for host epithelial cells and act as signalling molecules with anti-inflammatory, immunomodulatory, anti-oxidative, and improved mucosal barrier effects. 14 Fat can have effects on the microbiome by release and conversion of bile salts 15 and altering the microbiota composition. 16 However, it is critical to appreciate the limitations of this rapidly expanding research area. 17 Common to all microbiome studies is the inherent variability [intra-and inter-individual] and the fact that even minor variations in research and laboratory methodology dramatically affect findings; this includes sampling, storage, DNA extraction, amplification, sequencing protocols, and data analysis. 18, 19 Disease factors [location, activity, medication, and faecal consistency] also affect the microbiome 20, 21 and are often not taken into account. Most importantly, even clear associations between microbes and IBD do not establish cause and effect. 20, 22 Therefore, interpretation of findings requires caution and findings may not always be reproducible. Nevertheless, there are several emerging specificities regarding the microbiome in IBD: 2.1.1.1. Diversity The single most reproducible finding of studies on microbes in IBD is a reduction in α-diversity. Diversity is generally thought to represent community health; reduced diversity results in less flexibility and adaptation and is likely to impact negatively on the microbial functional capacity. Reduced diversity can be the result of taxa elimination and/or bloom of taxa that displace others. Both are likely to occur in IBD. 23 Reduced diversity as a marker of IBD could indicate pathogenic mechanisms; however, it also has prognostic value since reduced richness [representing number of species] predicts failure to respond to corticosteroids in children with severe UC. 24 Recently, a reduction in the diversity of mucosa-associated bacteria was found in paediatric UC at non-inflamed sites, suggesting that the microbial changes may be an inherent defect in IBD and not just the result of inflammation. 28 Other taxonomic groups are depleted in IBD, such as Clostridia, Ruminococcaceae, and Bifidobacteria, and at species level, many have reported losses of Faecalibacterium prausnitzii, which may also have functional roles. 22, 29 Beyond the identity of bacteria, one must also consider their spatial organisation, which is altered in IBD. 30 Some of the observed changes are mediated by access to nutrients and oxygen gradients. 31 2.1.1.3. Functional changes Current focus is shifting towards the functional capacity of the microbiome, as 'what are they doing' might be more important than 'who is there'. The European MetaHIT Project identified a functional microbial dysbiosis in patients with IBD, 32 supported also by others. 33 Metabolomic analyses of breath or faeces revealed differences in IBD versus controls, [eg reduced butyrate, acetate, and [tri]methylamine and elevated amino acid levels]. [34] [35] [36] Interestingly, individuals with UC appear to have defective or deficient production of SCFA. 37, 38 Furthermore, analysis of microbiota-derived small molecules, considered important mediators in microbe-microbe and microbe-host interactions, reveal a variety of biological actions, including antibiosis and immune modulation. 39 Further studies integrating the metagenome with proteome and/or metabolome data in IBD, and taking into account disease phenotypes, activity, and medication use, are needed.
The observed microbial perturbations can result from the disease itself, but may also contribute to inflammation as shown by transfer of microbiota from colitis models to wild-type donors 40, 41 and improvement of disease activity after decontamination of the gut lumen. 42, 43 So far, microbial modulation of disease activity by administration of probiotics or prebiotics showed limited efficacy. 44 However, findings mainly resulting from metabolic and animal studies clearly demonstrate that diet can affect gut homeostasis and immune function via the microbiome.
Research gaps:
• Establishing causality between diet, microbiome, and IBD is an important research gap. Priority should be given to a systems biology approach.
• Longitudinal studies investigating early life exposure including diet, microbiome, and other environmental factors on IBD onset are needed. • Stratification of patients by disease phenotype, specific microbial perturbations, and dietary intake will be necessary to develop successful therapeutic and/or preventive strategies.
• Studies evaluating the ability to modify the microbiota by dietary interventions, and the effect on disease in affected individuals, should be a priority.
Effect of diet on rodent models and cell lines
Multiple dietary components have been shown to cause or aggravate inflammation in animal models of IBD. 20, 28, [45] [46] [47] Due to the concise nature of this review, we will confine ourselves to landmark studies that demonstrate an association between dietary components and inflammation in IBD models, or those studies that best highlight research gaps. 20 They reported an increase in colitis severity in the MF group compared with PUFA-and LF-fed IL-10 -/-mice. Colitis was also associated with the bloom of colitogenic Bilophila wadsworthia in the MF group, and was dependent on exposure to MF-induced taurine conjugated bile acids. Sodium caprate in MF has been shown to increase intestinal permeability independently of the taurine dependent mechanism previously described. 20 High fat was also shown to accelerate ileitis in a tumour necrosis factor [TNF] ∆ARE/WT mouse model. 45 The same group subsequently demonstrated that gluten induced ileitis in these mice through the gluten-dependent increased intestinal permeability. 47 Adherence of AIEC via CEACAM6 appears to be critical for the pathogenic effect of this strain in human CD. Maltodextrin, a key polysaccharide used in sweeteners [Sucralose] and as a thickening agent, was shown to enable AIEC adherence and biofilm formation independently of the presence of CEACAM6. In a viewpoint article, Roberts and colleagues hypothesised that the increased incidence of CD could be attributed to a higher consumption of emulsifiers in processed foods. 55 In support of this hypothesis, Chassaing and colleagues 48 showed that TLR5 -/-and IL-10 -/-mice exposed to two common emulsifiers, carboxymethylcellulose and polysorbate-80, develop obesity/metabolic syndrome in TLR5 -/-and severe colitis in IL-10 -/-. Both mice strains fed the emulsifiers showed increased gut permeability, reduced mucus thickness, higher penetration of intestinal bacteria, and dysbiosis. These changes resulted in an accelerated metabolic syndrome in TLR5 -/-mice and in an increased incidence and extent of colitis and enrichment in Bilophila spp. in IL-10 -/-mice, with both CMC and polysorbate-80. In line with these results, translocation of E. coli across M cells was increased in the presence of polysorbate-80. 50 The studies outlined above accentuate the aggravating effect of HF diets in models of CD; however, the results to date on the effect of HF on disease in animal models of UC are inconclusive [56] [57] [58] [59] ─the reason being differences in diet composition [egfat/sugar ratio, n-3/ n-6 ratio], duration of diet consumption and type of model used. For example, HF or n-6 PUFA feeding to mice exposed to dextran sodium sulphate [DSS]-induced colitis resulted in either worsening or amelioration of disease. 56, 57, 59 In contrast, HF feeding to Mdr1
-/-, a spontaneous model of UC, led to worsening of colitis, although no colitis was observed in WT mice. 58 An exciting new concept involves 'humanised mice' which may contain human genes or microbiome. Studies involving diet with such models could shed more light on the interaction between diet, microbiome, and IBD in humans. An important research gap is the development of a model in which different food ingredients could be tested with relevance to the human condition.
In conclusion, the collected data point towards diet-induced effects on microbiota composition, epithelial responses, and inflammation, primarily in genetic susceptible animals and less in wild-type animals. The translational relevance of these findings to the human conditions is yet to be addressed.
• Studies should evaluate if improvement of intestinal inflammation can be achieved with dietary interventions in animal models.
• Development of experimental models as a platform for testing multiple dietary ingredients potential to cause or inhibit inflammation should be a priority.
Epidemiology linking diet with risk of IBD
Epidemiological evidence shows that individuals migrating from regions of low IBD prevalence to higher-prevalence regions are at increased risk of developing IBD. 60 Numerous studies have evaluated the association between pre-illness intake of specific nutrients such as fats, carbohydrates, and protein, and food groups such as fruits, vegetables, and meats, for UC. All were case-control studies and analysed dietary intake retrospectively. The most frequently reported food components associated with IBD were cereals, fibrecontaining food, bread, sugar and sugar-containing foods, fruits and vegetables, fat, sucrose, starch, or total carbohydrate and protein intake or energy drinks. 14, [61] [62] [63] [64] Despite methodological limitations, several prospective studies have consistently identified animal protein to be associated with increased risk of UC. 61, 64, 65 In the study by Jantchou et al., the highest tertile for consumption of animal protein had a hazard ratio of 3.29 for developing UC [p = 0.005]. Jowett et al. studied 191 UC patients, and they demonstrated a significant association between high meat intake and risk of relapse of UC. 65 Although several studies suggested significant associations of particular dietary habits in UC, 14 an equal or even higher number of studies could not confirm these findings. Since many of the current methodologies are based on historical food frequency questionnaires [FFQ] , the current evidence is not sufficient to draw firm conclusions on the role of specific nutrients in the aetiology of UC. Dietary ingredients in Western diets are not limited to the 'natural components' listed above. There is an increased consumption of food additives, such as sweeteners, emulsifiers, thickeners, preservatives, and food colourings. These products, some of which have been linked to IBD, 49, 62, 66 should be further investigated in large well-designed epidemiological studies that provide data regarding exposure to these products.
The Nurses' Health Study examined the association between fibre intake and incident IBD. Subjects consuming large amounts of fibre, particularly fruits, were less likely to be subsequently diagnosed with CD, although no association was observed for UC. 67 There is evidence for a gene-diet interaction in which variants in genes for fatty acid metabolism affect the relationship between IBD risk and PUFA consumption. 68 Together, these findings support the hypothesis that consumption of fruits and possibly vegetables, rather than meats and fats, can lower the risk of IBD. The study using the European Prospective Investigation into Cancer and Nutrition [EPIC] database prospectively investigated the impact of nutrition on IBD development. 69 The EPIC-IBD study is a sub-cohort involving a total of 401 326 initially healthy men between 1991 and 1998. In this large multicentre prospective study using dietary data from a validated FFQ, they did not find any associations between total dietary carbohydrate, sugars [monosaccharides and disaccharides], or starch intakes and the odds of developing CD and UC. D'Souza et al. assessed Canadian children for dietary patterns, and idenified a diet rich in fruit and vegetables [prudent diet] as protective for CD whereas a partial 'Western diet' increased risk for CD. 70 Research gaps:
• Risk associated with consumption of commercially processed food including, but not limited to nutrients, additives, and processing, should be assessed in longitudinal studies.
• Future studies should address dietary patterns rather than individual dietary components. In paediatrics, a meta-analysis of studies comparing EEN with standard treatment has demonstrated an overall combined remission rate for EEN of 73%, 74 whereas two large, single-centre studies have confirmed a treatment efficacy of approximately 80%. 71, 73 Similar remission rates were reported in studies conducted in adults, in particular one randomised controlled study that demonstrated that 21/30 adults refractory to steroids entered remission with EEN. 75, 76 However, the most recent meta-analysis demonstrated that steroids were more effective than EEN. 77 Studies on EN in adults are sparse, of poor quality, and therefore it is difficult to draw clear conclusions. Interestingly, and in contrast to steroids effect, EEN also has the potential to induce mucosal healing. In a prospective Australian study, 58% of patients had early endoscopic response, and one-third had complete transmural healing on small bowel imaging. 78 Disease severity and luminal disease seem to be the only significant predictors of response to EEN. 69, 70 According to the ECCO/ ESPGHAN consensus, EEN should be the first-line therapy to induce remission in children with active mild-to-moderate luminal CD. 79 There are no data supporting the use of EEN for extra-intestinal manifestations or penetrating disease.
Diet as induction and maintenance therapy in IBD
It has traditionally been speculated that use of EEN should be limited to patients with small bowel involvement; however, results from further meta-analyses have shown no difference in the efficacy of EEN when considering disease location. 73, 74, 80 Likewise, there are no confirmatory data on the effectiveness of such treatment in severe isolated Crohn's pancolitis, and no data for isolated oral or perianal disease.
The efficacy of EEN has been attributed to different mechanisms including bowel rest, anti-inflammatory effects, restoration of the epithelial barrier, and favourable changes in the intestinal microbiota. 81 As both polymeric and elemental formulas show similar efficiency, 76, 82 gut rest is unlikely to be the primary mechanism. More recently, the effect of EEN has also been related to the exclusion of specific components from the diet. 83 A few studies have demonstrated a decrease in pro-inflammatory 84 and an increase in anti-inflammatory molecules [TGF-β] 85 in response to EEN. Incubation of CD biopsies with elemental formula led to an increased ratio of IL-1Ra to IL-1 β compared with control samples. 86 Other authors confirmed the direct effect of a polymeric formula on colonic epithelial cell chemokine responses to the proinflammatory cytokine TNF-α. 87 At the mesenteric fat level, EEN treatment decreased pro-inflammatory adipokines [TNF-α and leptin] and increased adiponectin levels. 88 The effects of EEN on the intestinal barrier have mostly been clarified by in vitro or animal studies. In human colonic epithelial cells, EEN has been found to prevent epithelial barrier dysfunction in the presence of TNF-α. 89 In an IL-10 -/-mouse model of colitis, EEN treatment maintained normal gut barrier function and integrity and reversed inflammatory changes. 90 Profound changes in the composition of the mucosal microbiome induced by EEN have been suggested by pioneer investigations 91 and recently confirmed by several studies. Reduced diversity of the microbiota, occurring after a few days or weeks of EEN, has been frequently reported. [92] [93] [94] [95] The microbiome effect induced by EEN differs from that induced by anti-TNF medications and most importantly from partial EN [PEN] . 96 In contrast, one study demonstrated an increase in species diversity after an elemental diet. 97 Speciesspecific effects induced by EEN were reported by different authors, particularly a significant decrease in Bacteroides. [92] [93] [94] 98 A reduction of F. prausnitzii was observed both in adults 99 and children, 92 challenging the previous paradigm of a protective role in CD. Reports describing changes in the intestinal metabolic profile are unequivocal.
92,100 A single study reported the metagenomic changes induced by EEN, particularly an increase in relative abundance of genes involved in cell growth and renewal and possibly in tissue healing. 95 The efficacy of EEN related to the exclusion of some dietary components is indirectly supported by studies indicating that PEN associated with a normal diet did not induce remission, 72 whereas 70% of children and 69% of adults on a PEN combined with a specific CD exclusion diet achieved remission. 83 Furthermore, specific dietary restriction seems to be therapeutic in CD. 101, 102 There are not enough studies to determine the optimal duration of EEN; the reported duration of an induction therapy varied from 2 to 12 weeks in studies; however, it is most frequently used for 6 to 8 weeks. If the clinical response is not achieved within 3 weeks, an alternative treatment should be considered. There is a paucity of evidence to guide the reintroduction of normal food after the end of EEN. There are few studies that have evaluated reintroduction of foods. Faiman et al. demonstrated that rapid food reintroduction [3 days] after EEN is equally as effective as delayed food reintroduction [5 weeks] after follow-up of 1 year. 103 Research gaps
• Mechanisms of action of EEN need to be explored, including the interaction of epigenetic, immunological, and microbiological changes.
• Studies evaluating the reintroduction of specific foods following EEN need to be performed.
• EEN should be evaluated in a variety of conditions, including adults with CD, in UC, complicated CD, and pre-and postoperative settings. 104 The mechanisms via which PEN might impact on CD activity, if at all, are poorly understood. Unlike EEN, the complete removal of dietary antigen as a hypothetical mechanism is no longer the case; therefore if studies indicate that PEN is at least as effective as EEN, then this might also exclude such removal as a mechanism for the effectiveness of EEN.
Partial enteral nutrition in management of IBD
Type of supplementation varies widely between studies and clinical practice. 72, 83, [105] [106] [107] [108] [109] [110] The volume investigated has ranged from 35% to 90% of total energy requirements, and the food consumed can either be a free diet or a defined restrictive diet. A small number of studies have investigated PEN compared with normal diet for maintenance of remission. 105 109 At 12 months, PEN resulted in lower relapse rates, lower disease activity, and lower endoscopic inflammation compared with normal diet. In an identical study published by the same group but in those with surgically induced remission, PEN was confirmed to lower relapse rates and endoscopic recurrence compared with normal diet at 12 months, 110 whereas in those with infliximab induced remission, it was not shown to affect relapse rates. 113 Finally a retrospective, non-randomised trial in children with EEN-induced remission compared relapse rates in those who chose to continue nocturnal PEN compared with those who did not. 112 PEN reduced relapse rate at both 6 months and 12 months.
There is only one RCT of PEN in the treatment of active CD in comparison with normal diet. This was a randomised, cross-over trial in adults with on average very mildly active CD and malnutrition. 114 Although some nutritional markers were improved, PEN did not impact on disease activity [Harvey-Bradshaw Index]. 114 One RCT has compared elemental PEN and EEN for induction of remission in children with moderate to severely active disease over a 6-week period. However, PEN resulted in fewer patients entering remission and a smaller reduction in the Paediatric Crohn's Disease Activity Index [PCDAI] compared with EEN. 72 A recent, non-randomised trial compared PEN with EEN or anti-TNF treatment for the treatment of active CD in children/ adolescents, with patients allocated to the intervention based upon the unit in which they were recruited. 115 At 8 weeks, fewer patients receiving PEN had a clinical response compared with either EEN or anti-TNF treatment, and fewer were in clinical remission. However, the limitation of non-randomised treatment allocation and clinically important differences in baseline characteristics make interpretation of these findings difficult. 115 One uncontrolled trial has investigated PEN in conjunction with a CD exclusion diet in children/young adults, reporting a clinical response in 78.7% and 70.2% entering full disease remission. 83 Research gaps
• Investigation of the effectiveness of PEN as a monotherapy or in combination with medical therapy for preventing relapse in IBD is a research gap.
• The optimal regimen of PEN for maintenance of CD, including the dose, composition, duration, method of delivery of feeding, and nature of the accompanying oral diet should be identified.
Elimination diets in management of IBD EEN is an effective therapy for induction of remission in CD 74
; however, there are drawbacks. EEN is difficult to adhere to, particularly in adults, 104 and there is limited evidence for post-EEN strategy. Understanding the mechanism of response could lead to diets that are easier to comply with and follow, which could be implemented for longer duration.
Several elimination diets have been developed and evaluated for induction of remission, maintenance of remission, or improvement of functional symptoms [Supplementary 122 Only one study for UC met requirements for outcomes. 123 A summary of these diets is presented in Supplementary Table 2. However, only two diets [SCD and CDED] reported significant improvement in clinical remission and data demonstrating a significant reduction in inflammation, and therefore are discussed here.
The theoretical assumption underlying the SCD is that CD is caused by malabsorption of disaccharides and complex carbohydrates resulting in bacterial overgrowth and intestinal injury. 124 Cohen et al. 116 conducted a prospective paediatric study in nine children with active CD, using the SCD. Patients were evaluated using the PCDAI, Harvey-Bradshaw Index The original rationale for the low FODMAP diet in IBD was that several dietary FODMAPs may undergo fermentation that may cause tissue injury as a result of increased intestinal permeability. 126 The use of the FODMAP diet to manage functional symptoms in patients with IBD will be discussed later in this topical review.
In conclusion, dietary manipulation offers promise for IBD. However, there is an urgent need for RCTs to evaluate the efficacy of those diets together with their effect on the microbiota.
Research gaps
• Clinical trials to develop and evaluate efficacy of elimination diets for induction and maintenance of remission in IBD are required. • Dietary ingredients added or eliminated which are responsible for the clinical effects, and definition of mechanisms underlying response, need to be identified.
Assessment of nutritional status and supportive nutritional therapy in IBD
Malnutrition is an extra-intestinal manifestation of IBD, comprising undernutrition and overnutrition. It presents with different forms via a range of mechanisms, and its severity varies during the natural course of IBD [ Supplementary Figure 2 , available as Supplementary data at ECCO-JCC online]. The origin and manifestations of undernutrition in IBD are multifactorial and include suboptimal nutritional intake, alterations in energy/nutrient requirements and metabolism, malabsorption, excessive gastrointestinal losses, and medication. 4 Although literature is still inconclusive, a higher basal metabolic rate:FFM ratio has regularly been reported in IBD patients compared with healthy controls, [127] [128] [129] and children with CD fail to adapt their resting energy expenditure [REE] per kg lean mass to the same extent that patients with anorexia do. 127 In adult CD patients, malabsorption is a major contributor to being underweight when in remission, 130 and impaired gastric acid and pancreatic enzyme secretion were observed in undernourished patients. 131 The effect of proinflammatory cytokines on energy/nutrient requirements, bone, and development can also interact independently in the aetiology of undernutrition. 132 Physical activity as contributor of total energy expenditure has barely been studied. 133 Hence, assessment of nutritional status and prevention and correction of deficits are imperative and the cornerstone to multidisciplinary management of IBD patients.
Assessment of nutritional status
Involuntary weight loss and being underweight are common features of the newly diagnosed IBD patient and frequently accompany episodes of disease relapse. Whereas underweight is more common in CD than UC, presenting in approximately 60% and 35% of new cases, respectively, 4 recent evidence suggests that fewer patients currently present underweight, reflecting either the obesity epidemic or earlier disease recognition. 134, 135 There are limited data on the progression of undernutrition following diagnosis and whether this is predictive of disease outcomes. In a paediatric study, a similar proportion of children with CD had short stature 2 years post-diagnosis, but being underweight decreased dramatically from 35% to 2%. 134 IBD-specific alterations in body composition, with depletion of lean mass and normal or increased fat mass have been consistently reported. 136 Hence, a high degree of adiposity and less lean mass should be expected for a given BMI. Interestingly, normalisation of BMI at 2 years' follow-up has not been associated with an increment in fat-free mass [FFM] in CD, 137 which suggests that BMI changes may not be good proxies for body composition changes in IBD. Such features of sarcopenia might be clinically relevant, as people with IBD may have an increased risk of cardiovascular events, 138 and recently intra-abdominal body composition has been associated with adverse clinical outcomes. However, both of these findings need to be replicated in prospective studies. 139, 140 Osteopenia and osteoporosis are often seen in CD. Adult patients have a 60-70% higher risk for vertebral and hip fracture incidence compared with healthy controls. 59, 141 In children, data are not suggestive of increased fracture risk during childhood, but it might be that a higher risk of fracture occurs early in adulthood. Up to 25% of CD patients will present with growth deficits, and a proportion will not attain their height predicted by genetic potential. 142 Whereas clinical presentation of frank micronutrient deficiencies in IBD is rare and largely limited to case reports, low circulating levels are reported for most of micronutrients. 4, 143 However, caution should be exercised in the interpretation of plasma micronutrient measurements in the presence of systemic inflammatory response [eg high CRP]. Plasma concentrations of various micronutrients [eg iron, zinc, selenium, copper, vitamins A, C, and E] are substantially affected by nutrient carrier protein concentration changes [144] [145] [146] and so are unlikely to reflect total body reserves, and inappropriate clinical interpretation may trigger unnecessary interventions. 147 Development of novel biomarkers of micronutrient body stores is required, and dietary intake assessment should complement biochemical indices.
In contrast to the wealth of data on clinical diagnostics and pharmacological management of IBD, limited data have explored the frequency of routine nutritional assessment and management of IBD, particularly in elderly patients where data are scarce. Data from a UK survey identified adult service resource gaps/shortages and absence of uniform practice standards in nutritional assessment and management. 104 Assessment of nutritional status requires at least measurement and interpretation of anthropometry and dietary intake, making dietitians integral members of the multidisciplinary team caring for patients with IBD. 148 Assessment of body composition using sophisticated techniques is appealing, but the implications of this for clinical practice improvement and patient benefit need to be explored to justify the resources used.
• There are limited data on the evolution of malnutrition following diagnosis and whether this is predictive of disease outcomes.
• New biomarkers of micronutrient status are needed to overcome limitations of plasma measurements in the presence of systemic inflammatory response.
• More research is needed on nutritional status and management of IBD patients, particularly in pregnancy, the elderly, and the preoperative state. [149] [150] [151] Retrospective case-control studies report that early onset, family history of IBD, stricturing disease, younger age at first surgery, surgical complications, and delay in diagnosis predispose towards SBS and intestinal failure in IBD. [152] [153] [154] [155] [156] Since SBS is accompanied by reduced intestinal surface, a biomarker is needed to diagnose clinically significant reduced intestinal mass/intestinal function and monitor adaptation and mucosal healing. Potential biomarkers are serum citrulline [generation test] and intestinal fatty acid binding protein [I-FABP] . [157] [158] [159] Studies on biomarkers that can predict or diagnose the presence of intestinal failure/intestinal insufficiency are required.
Glucagon-like peptide-2 [GLP-2; teduglutide] enhances structural adaptation of the small intestinal mucosa in patients with SBS. [160] [161] [162] Studies are lacking on the reparative [adaptation, mucosal healing] and immunomodulatory effects of GLP-2 in IBD patients with SBS.
Intestinal transplantation may be considered in intestinal failure, as a high-risk, last option treatment. A prospective study in 20 CD patients with chronic intestinal failure, who were dependent on parenteral nutrition [PN] , suggested that a scoring system enables the physician to identify which patients may benefit from intestinal transplantation before PN-associated secondary organ failure develops. 163 Further work assessing which CD patients with intestinal failure receiving PN will benefit from intestinal transplantation are necessary to improve clinical and patient outcomes.
Enterocutaneous fistula can often be a serious complication of CD. Aggressive nutritional support to treat sepsis and reverse catabolic state can improve outcome. 164 Enteral nutrition for 3 months is an effective therapeutic strategy 165 and can prevent enterocutaneous fistula postoperatively in CD. 166 PN can also have a supportive role where enteral nutrition is compromised, but evidence is lacking on the efficacy to heal enterocutaneous fistula and other complicated fistulas in CD patients. 167 Whether EN or PN is the more effective nutritional strategy in patients with fistulising CD needs to be further elucidated.
High-output stomas in CD are common within 3 weeks of ileostomy and resolve spontaneously in almost half of patients, whereas the remaining need ongoing treatment due to a short small-intestinal remnant. Successful treatments include hypotonic fluid restriction, oral rehydration solution, salt-rich diets, exclusive enteral nutrition, and/or short-term parenteral electrolytes. [168] [169] [170] [171] Prospective research on optimal nutritional strategies to manage high-output stomas in IBD, preventing dehydration and avoiding acute hospital admission [eg hypotonic fluid restrictions and/or oral rehydration solutions, intravenous glucose-sodium] should be compared with 'free diet'. Patient reported outcomes [eg quality of life] should also be considered.
Multiple factors relating to clinical, social, and economic issues contribute to lower quality of life [QOL] in patients dependent upon home PN. 172 Living with CD and intestinal failure reduces QOL and hugely affects day-to-day living and inhibits autonomy. 173 However, there is limited research on QOL in CD patients with SBS.
Multidisciplinary team working is crucial for optimising the management of SBS/intestinal failure in IBD. 174 The contribution of the dietitian is important where available, but when not available it is unknown whether there are failings in clinical and patient outcomes.
• New biomarkers that can predict, diagnose, monitor intestinal failure or intestinal insufficiency are needed in IBD.
• Nutritional treatment strategies for the management of highoutput stoma and intestinal failure/insufficiency in IBD need to be developed.
Supportive nutritonal therapy for functional bowel symptoms in IBD
Functional bowel symptoms include abdominal pain, bloating, increased flatulence, and diarrhoea and/or constipation, and affect 35% of patients with inactive IBD 175 ; however, these symptoms can be mistaken for active IBD. Patients with IBD and coexisting functional bowel symptoms also exhibit increased anxiety/depression and reduced QOL compared with patients without. 176 Clinical [symptoms] and objective (histological and inflammatory markers [eg faecal calprotectin, CRP]) assessment help to distinguish between functional bowel symptoms and active IBD, although often the diagnostic validity is poor. 177, 178 Identification of functional bowel symptoms in inactive IBD is of utmost importance to ensure that unnecessary and potentially harmful treatment strategies are avoided; conversely, presence of active IBD lesions should be excluded before determining that symptoms are functional in nature.
Treatment strategies similar to those used in irritable bowel syndrome [IBS], such as antispasmodics, antidiarrhoeals, and low-dose antidepressants, can be used for functional bowel symptoms in IBD, but there is limited research on their safety and effectiveness in IBD. From a dietary perspective, identification of dietary triggers can be helpful, 179 but is difficult to determine the culprits due to the complexity of the diet and delay of symptom generation following consumption of the food or ingredient. In IBS, alteration of dietary fibre intake can be beneficial, 180, 181 but there is limited research on functional bowel symptoms in IBD. A low [FODMAP] diet is recognised as a successful management strategy for functional bowel disorders like IBS. 180, 182 FODMAPs are poorly absorbed carbohydrates that can increase small intestinal luminal water and colonic fermentation by the gastrointestinal microbiota [183] [184] [185] which, in susceptible individuals, induces functional bowel symptoms. 182 Some FODMAPs are prebiotic (eg fructo-oligosaccharides [FOS] and galacto-oligosaccharides [GOS]), presumably having a beneficial effect on the gastrointestinal microbiota. In IBS, short-term FODMAP reduction correlates with reduced luminal Bifidobacterium spp. and F. prausnitzii, 186, 187 which may negatively impact on the gastrointestinal microbiome. For this reason, the low FODMAP diet incorporates short-term FODMAP restriction [4-8 weeks] to induce symptom control, followed by FODMAP reintroduction using food challenges to personal tolerance. Thus, in the long-term, only high FODMAP foods that trigger symptoms are avoided, maintaining long-term nutritional adequacy. 188 Whether the gastrointestinal microbial changes seen following FODMAP restriction return to normal in the long term is unknown.
In active Crohn's disease, an RCT of FOS supplementation significantly increased the incidence and severity of abdominal symptoms compared with placebo, although it was not known if any of these patients had concomitant IBS. 189 A double-blind cross-over rechallenge RCT in patients with inactive IBD and functional bowel symptoms, who had responded to a low FODMAP diet, showed that FOS, but not GOS or the polyol sorbitol, induced symptoms. 190 In a retrospective case note review of 72 IBD patients [CD = 52] who had previously received low FODMAP dietary advice, 56% reported overall symptom improvement. 121 A prospective study of the low FODMAP diet in 88 IBD patients [CD = 39] showed significantly more patients reported satisfactory relief from their functional bowel symptoms at follow-up [78%] compared with baseline [16%; p < 0.001]. 191 Abdominal pain, bloating, flatulence, belching, incomplete evacuation, nausea, and heartburn also improved. Similar findings were reported when Crohn's and ulcerative colitis were sub-analysed. 
Conclusions
Hereby, we provide a summary of our current knowledge and emerging evidence on the broad role of diet and nutrition in the aetiology and management of IBD. The subject is topical and findings of current and future multidisciplinary research are expected to have major impact on understanding the dietary influences of CD onset and improving dietary therapies in all aspects of IBD management. We propose a list of research gaps that we anticipate to set the future research agenda in the topic of nutrition and diet in IBD.
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